Dagrocorat

From WikiMD's Wellness Encyclopedia

Dagrocorat is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed.

Error creating thumbnail:
Dagrocorat

Developmental code name[edit | edit source]

The delopmental code names were: PF-00251802, PF-251802

Never marketed[edit | edit source]

The medication was never marketed by the pharmaceutical company for unknown reasons.

Mechanism of action[edit | edit source]

Dagrocorat is a novel and dissociated glucocorticoid receptor agonist.

Originator[edit | edit source]

Pfizer

Class of drug[edit | edit source]

Anti-inflammatories; Antirheumatics; Phenanthrenes; Pyridines; Small molecules

Orphan Drug Status[edit | edit source]

No

New Molecular Entity[edit | edit source]

Yes

Highest Development Phases[edit | edit source]

Phase 1

Current status[edit | edit source]

Discontinued

Proposed indication[edit | edit source]

Rheumatoid arthritis

Most Recent Events[edit | edit source]

  • 27 Jan 2010Discontinued - Phase-I for Rheumatoid arthritis in USA (unspecified route)
  • 03 Oct 2008Phase-I trials in Rheumatoid arthritis in USA (unspecified route)

Related molecules[edit | edit source]

Dagrocorat-2


Contributors: Prab R. Tumpati, MD